Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

In his inaugural article in the Proceedings of the National Academy of Sciences as an NAS member (elected 2021), Prof Mike Dustin and his research team have explained how messages are passed across the immunological synapse. The research could have implications for future vaccine development and immunotherapy treatments.

An activated CD4+ T cell (white) has pushed T cell receptor loaded extracellular vesicles (cyan) onto an antigen presenting cell (APC) and pulled antigen (magenta) from the APC into the T cell.

The work started with Audun Kvalvaag's interest in clathrin, a protein that is well known for its role in bringing substances such as cholesterol and iron into cells for nutrition, and to generate small packages of information that can be released from cells called exosomes. Dr. Kvalvaag, a visiting scholar from Oslo, Norway, led the team in Dustin's lab that identified new roles of clathrin in the immunological synapse.

"Using state of the art microscopy tools, including the eTIRF-SIM that was custom built at the Kennedy Institute, we have found that clathrin is a common scaffold for pushing messages from T cells onto antigen presenting cells (APCs), and pulling messages into the T cells from the APCs," said Audun. "Messages in the form of vesicles are pushed directly from the plasma membrane of T cells through a process we termed clathrin- and ESCRT-mediated ectocytosis (CEME), while T cells pulling vesicles from the APCs is based on the process of clathrin-mediated endocytosis (CME). The choice of which direction the vesicles move is controlled by different adaptors, called HRS and EPN1, respectively."

The immunological synapse is the crossroads of the adaptive immune system, through which helper T cells instruct B cells to induce antibody production or killer T cells latch onto infected and cancerous cells to eradicate them.

During activation, T cell receptors attach to peptide–MHC (pMHC) complexes and initiate T cell activation and TCR ubiquitination. Dustin and colleagues have championed the idea that ubiquitinated TCRs can be ectocytosed by the T cell and pushed toward the antigen-presenting cell in extracellular vesicles, but how this was reconciled with many prior observations of T cells pulling pMHC from the antigen presenting cell into the T cell was a mystery. This study found that clathrin in fact governs both processes through bidirectional membrane exchange at the immunological synapse. The choice of direction of movement is coordinated by the adaptors that link the TCR to clathrin to enable ectocytosis or endocytosis.

In the first instance, clathrin is recruited to TCR microclusters by HRS to initiate release of TCR by CEME. Subsequently, EPN1 recruits clathrin to remaining TCR-pMHC clusters to enable trans-endocytosis of engaged pMHC from the antigen presenting cell.

"Based on this information we may be able to engineer T cells to be better communicators at the crossroads," said Michael, "which has implications for vaccination and cancer immunotherapy".

Similar stories

Fat tissues can play a protective role against inflammation in the intestine

A new study in The EMBO Journal has revealed how fat tissues might provide a protective role in intestinal inflammation opening new lines of research into the treatment of inflammatory bowel diseases.

New drug offers hope for people with hand osteoarthritis

A new study, published in Science Translational Medicine by researchers at the University of Oxford has identified that Talarozole, a drug that is known to increase retinoic acid, was able to prevent osteoarthritis (OA) in disease models.

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

MRC funding awarded to Kennedy researchers

Two new projects led by Tal Arnon and Irina Udalova have been awarded Medical Research Council (MRC) funding.

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.

New research suggests targeting blood vessels could be key to controlling fibrotic disease

By studying blood vessels at single cell resolution, Professor Jagdeep Nanchahal and colleagues found that in Dupuytren’s disease, a fibrotic disorder of the hand, the vasculature is key to orchestrating the development of human fibrosis.